These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 2783661

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
    Shiao RT, McLeskey SB, Khera SY, Wolfson A, Freter CE.
    Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody.
    Gougelet A, Mansuy A, Blay JY, Alberti L, Vermot-Desroches C.
    PLoS One; 2009 Nov 30; 4(11):e8026. PubMed ID: 19956602
    [Abstract] [Full Text] [Related]

  • 50. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E, Terpos E, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G, Gerotziafas G, Christakis J, Zervas K.
    Hematol Oncol; 2004 Dec 30; 22(4):159-68. PubMed ID: 15991268
    [Abstract] [Full Text] [Related]

  • 51. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.
    Ann Hematol; 2003 Jan 30; 82(1):19-23. PubMed ID: 12574959
    [Abstract] [Full Text] [Related]

  • 52. Role of interleukin 16 in multiple myeloma.
    Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kröger N.
    J Natl Cancer Inst; 2012 Jul 03; 104(13):1005-20. PubMed ID: 22745469
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Four cell-secreted cytokines act synergistically to maintain long term proliferation of human B cell lines in vitro.
    Abken H, Fluck J, Willecke K.
    J Immunol; 1992 Oct 15; 149(8):2785-94. PubMed ID: 1328386
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. [Bone and myeloma].
    Ravaud P, Roux C.
    Rev Prat; 1993 Feb 01; 43(3):293-7. PubMed ID: 8502958
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
    Zannettino AC, Farrugia AN, To LB, Atkins GJ.
    Methods Mol Med; 2005 Feb 01; 113():245-56. PubMed ID: 15968108
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.